113 related articles for article (PubMed ID: 35133094)
1. The Prediction of HER2-Targeted Treatment Response Using
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Lee KC; Kang CM; Seong MK; Kim HA; Noh WC; Lim SM
J Breast Cancer; 2022 Feb; 25(1):69-73. PubMed ID: 35133094
[TBL] [Abstract][Full Text] [Related]
2. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of HER2 targeted 64 Cu-DOTA-tagged PET imaging in gastric cancer patients.
Hernandez MC; Yazaki P; Mortimer JE; Yamauchi D; Poku E; Park J; Frankel P; Kim J; Colcher DM; Wong J; Fong Y; Shively J; Woo Y
Nucl Med Commun; 2023 Dec; 44(12):1151-1155. PubMed ID: 37901917
[TBL] [Abstract][Full Text] [Related]
4. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Tamura K; Kurihara H; Yonemori K; Tsuda H; Suzuki J; Kono Y; Honda N; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Hasegawa K; Kanayama Y; Nozaki S; Kinoshita T; Wada Y; Tazawa S; Takahashi K; Watanabe Y; Fujiwara Y
J Nucl Med; 2013 Nov; 54(11):1869-75. PubMed ID: 24029656
[TBL] [Abstract][Full Text] [Related]
5. (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.
Kurihara H; Hamada A; Yoshida M; Shimma S; Hashimoto J; Yonemori K; Tani H; Miyakita Y; Kanayama Y; Wada Y; Kodaira M; Yunokawa M; Yamamoto H; Shimizu C; Takahashi K; Watanabe Y; Fujiwara Y; Tamura K
EJNMMI Res; 2015; 5():8. PubMed ID: 25853014
[TBL] [Abstract][Full Text] [Related]
6. Tumor Uptake of
Mortimer JE; Bading JR; Park JM; Frankel PH; Carroll MI; Tran TT; Poku EK; Rockne RC; Raubitschek AA; Shively JE; Colcher DM
J Nucl Med; 2018 Jan; 59(1):38-43. PubMed ID: 28637802
[TBL] [Abstract][Full Text] [Related]
7. Use of
Mortimer JE; Bading JR; Frankel PH; Carroll MI; Yuan Y; Park JM; Tumyan L; Gidwaney N; Poku EK; Shively JE; Colcher DM
J Nucl Med; 2022 Aug; 63(8):1145-1148. PubMed ID: 34857660
[TBL] [Abstract][Full Text] [Related]
8. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
[TBL] [Abstract][Full Text] [Related]
9. Towards integration of
Jarrett AM; Hormuth DA; Adhikarla V; Sahoo P; Abler D; Tumyan L; Schmolze D; Mortimer J; Rockne RC; Yankeelov TE
Sci Rep; 2020 Nov; 10(1):20518. PubMed ID: 33239688
[TBL] [Abstract][Full Text] [Related]
10. A preliminary clinical trial to evaluate
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
[TBL] [Abstract][Full Text] [Related]
11. [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice.
Schjoeth-Eskesen C; Nielsen CH; Heissel S; Højrup P; Hansen PR; Gillings N; Kjaer A
J Labelled Comp Radiopharm; 2015 May; 58(6):227-33. PubMed ID: 25906708
[TBL] [Abstract][Full Text] [Related]
12. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
[TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
14. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of [
Dehdashti F; Wu N; Bose R; Naughton MJ; Ma CX; Marquez-Nostra BV; Diebolder P; Mpoy C; Rogers BE; Lapi SE; Laforest R; Siegel BA
Breast Cancer Res Treat; 2018 Jun; 169(3):523-530. PubMed ID: 29442264
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.
Beylergil V; Morris PG; Smith-Jones PM; Modi S; Solit D; Hudis CA; Lu Y; O'Donoghue J; Lyashchenko SK; Carrasquillo JA; Larson SM; Akhurst TJ
Nucl Med Commun; 2013 Dec; 34(12):1157-65. PubMed ID: 24100444
[TBL] [Abstract][Full Text] [Related]
18. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
20.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
